Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc. (DAWN) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · DAWN · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
13
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Day One Biopharmaceuticals, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
DAWN insider buying and selling by quarter
DAWN insider selling · DAWN insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · DAWN ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
DAWN executive sell shares · DAWN board member insider trading · DAWN insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Apr 23, 2026 | AI Day1 LLC 10 percent owner | Other | 12,929,322 | $277.98M⚡ | Form 4 |
| Apr 23, 2026 | Bender Jeremy CHIEF EXECUTIVE OFFICER · Director | Other | 808,285 | $81 | Form 4 |
| Apr 23, 2026 | VASCONCELLES MICHAEL Head of Research and Dev. | Other | 4,397 | $0 | Form 4 |
| Apr 23, 2026 | York Charles N II COO and CFO | Other | 312,025 | $31 | Form 4 |
| Apr 23, 2026 | Dubow Adam Gen Counsel & Secretary | Other | 72,694 | $7 | Form 4 |
| Apr 23, 2026 | Holles Natalie C. Director | Other | 57,310 | $6 | Form 4 |
| Apr 23, 2026 | Ramasastry Saira Director | Other | 40,485 | $4 | Form 4 |
| Apr 23, 2026 | Josey John A. Director | Other | 72,292 | $7 | Form 4 |
| Apr 23, 2026 | Merendino Lauren Chief Commercial Officer | Other | 60,157 | $6 | Form 4 |
| Feb 15, 2026 | Merendino Lauren Chief Commercial Officer | Option | 4,625 | — | Form 4 |
| Feb 15, 2026 | Merendino Lauren Chief Commercial Officer | Option | 3,687 | — | Form 4 |
| Feb 17, 2026 | Merendino Lauren Chief Commercial Officer | Sale | 5,814 | $67K | Form 4 |
| Feb 15, 2026 | Merendino Lauren Chief Commercial Officer | Option | 3,688 | — | Form 4 |
| Feb 15, 2026 | Merendino Lauren Chief Commercial Officer | Option | 3,162 | — | Form 4 |
| Feb 15, 2026 | Dubow Adam Gen Counsel & Secretary | Option | 4,375 | — | Form 4 |
| Feb 15, 2026 | Dubow Adam Gen Counsel & Secretary | Option | 3,687 | — | Form 4 |
| Feb 17, 2026 | Dubow Adam Gen Counsel & Secretary | Sale | 6,395 | $74K | Form 4 |
| Feb 15, 2026 | Dubow Adam Gen Counsel & Secretary | Option | 3,688 | — | Form 4 |
| Feb 15, 2026 | Dubow Adam Gen Counsel & Secretary | Option | 1,750 | — | Form 4 |
| Feb 15, 2026 | Dubow Adam Gen Counsel & Secretary | Option | 2,963 | — | Form 4 |
| Feb 15, 2026 | York Charles N II COO and CFO | Option | 7,875 | — | Form 4 |
| Feb 17, 2026 | York Charles N II COO and CFO | Sale | 6,065 | $70K | Form 4 |
| Feb 15, 2026 | York Charles N II COO and CFO | Option | 6,625 | — | Form 4 |
| Feb 15, 2026 | York Charles N II COO and CFO | Option | 6,625 | — | Form 4 |
| Feb 15, 2026 | York Charles N II COO and CFO | Option | 2,250 | — | Form 4 |
AI Day1 LLC
10 percent owner
Date
Apr 23
Shares
12,929,322
Price
$21.50
Value
$277.98M ⚡
Bender Jeremy
CHIEF EXECUTIVE OFFICER · Director
Date
Apr 23
Shares
808,285
Price
$0.00
Value
$81
VASCONCELLES MICHAEL
Head of Research and Dev.
Date
Apr 23
Shares
4,397
Price
$0.00
Value
$0
Merendino Lauren
Chief Commercial Officer
Date
Apr 23
Shares
60,157
Price
$0.00
Value
$6
Merendino Lauren
Chief Commercial Officer
Date
Feb 15
Shares
4,625
Price
—
Value
—
Merendino Lauren
Chief Commercial Officer
Date
Feb 15
Shares
3,687
Price
—
Value
—
Merendino Lauren
Chief Commercial Officer
Date
Feb 17
Shares
5,814
Price
$11.60
Value
$67K
Merendino Lauren
Chief Commercial Officer
Date
Feb 15
Shares
3,688
Price
—
Value
—
Merendino Lauren
Chief Commercial Officer
Date
Feb 15
Shares
3,162
Price
—
Value
—
Dubow Adam
Gen Counsel & Secretary
Date
Feb 17
Shares
6,395
Price
$11.60
Value
$74K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About DAWN insider trading
DAWN insider trades
Day One Biopharmaceuticals, Inc. (DAWN) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Bender Jeremy (CHIEF EXECUTIVE OFFICER · Director), Dubow Adam (Gen Counsel & Secretary), York Charles N II (COO and CFO). Over the past 12 months, 5 insiders have filed transactions with the SEC. DAWN insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Day One Biopharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
DAWN insider trading · 5 questionsThe insiders of Day One Biopharmaceuticals, Inc. (DAWN) include executives and directors such as Bender Jeremy (CHIEF EXECUTIVE OFFICER · Director), Dubow Adam (Gen Counsel & Secretary), York Charles N II (COO and CFO), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026